• COINS and cross-border capital — U.S. restrictions are widely expected to pass, but investors and companies are already ...
Democrats will take control of Congress in January with a clear mandate to improve affordability, renewed animus toward the ...
Turning tumors into local immunotherapy factories is among the strategies highlighted in preclinical cell, gene, and mRNA ...
Alethio wants to lower platelet counts in essential thrombocythemia and shrink the malignant clone that drives their ...
Building better biological AI models requires more than simply generating more data. Four initiatives launched or expanded in ...
FDA approved the first plasmid DNA-based immunotherapy in October, granting accelerated approval to Inovio’s Voceryq ...
Caspian is developing an oral menin inhibitor to regenerate patients’ own pancreatic beta cells, with plans to begin testing ...
For more than a decade, it has been clear that U.S. clinical trials are too slow, too costly, and too far removed from the ...
Only about 5% of rare diseases have an approved therapy, and this is unlikely to change without novel development processes.
FDA has at least eleven PDUFA dates on its November calendar, 10 of which are for new products. First up is PD-1 x VEGF ...
Antibody-drug conjugates accounted for more first-in-human studies than any other modality at ESMO 2026, highlighting their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results